-+ 0.00%
-+ 0.00%
-+ 0.00%
Yuanda Pharmaceutical (00512): GPN01564, a globally innovative nebulized inhaler for the treatment of respiratory syncytial virus, was approved for phase I clinical research
Share
Listen to the news

Zhitong Finance App News, Yuanda Pharmaceutical (00512) issued an announcement. GPN01564, a globally innovative nebulized inhaler for the treatment of respiratory syncytial virus (RSV) independently developed by the Group, was approved by the National Drug Administration (NMPA) of the People's Republic of China to carry out phase I clinical research. This is another major milestone in the Group's fight against infections in the respiratory and critical care fields.

GPN01564 is an RSV fusion protein (F protein) inhibitor. F protein is a type I membrane fusion protein. Due to its unique antigen epitope conformation and ability to efficiently neutralize antibodies, it has become one of the most promising targets in the field of RSV prevention and treatment research; at the same time, this product relies on an atomized inhalation route and does not require systemic administration. The drug directly targets the lungs to achieve accurate and non-invasive administration, which can improve the medication experience and form a clear clinical advantage in dosage compliance. Pre-clinical research results show that GPN01564 has good pharmacogenicity, safety, and efficacy.

RSV is one of the main causes of lower respiratory infections. Although people of any age can be infected with RSV, it is usually more severe in infants, especially premature infants, children with chronic lung disease or congenital heart disease (CHD), and the elderly. According to statistics, in 2019, there were 33 million people worldwide with acute lower respiratory infections (ALRTIS) due to RSV; RSV causes more than 3.6 million cases of children under 5 to be hospitalized every year, including about 100,000 deaths. China is one of the countries with the highest number of cases of RSV infection in the world. In 2019, there were about 3.5 million cases of alRTIS caused by RSV in children under 5 in China, accounting for more than 10% of the world, and 620,000 to 950,000 hospitalizations, accounting for 17% to 24% of the world, ranking second in the world. Currently, for RSV infections, only monoclonal antibodies and vaccines can be used to prevent infection in infants and the elderly. According to the “Collaborative Expert Consensus on the Prevention and Control of Respiratory Syncytial Virus Infection”, since there are currently no specific antiviral drugs for RSV infections, symptomatic supportive treatment such as oxygen therapy and rehydration is mainly given as appropriate according to the individual conditions of infected people. It can be seen from this that clinical needs in the field of treatment of RSV infections are far from being met.

GPN01564 is an important product reserve for the Group's innovative anti-infection platform in the respiratory and critical care sector. It forms a collaborative product portfolio with innovative products sold by the sector to form a closed loop of full-airway and full-cycle management in the respiratory sector: the novel compound nasal spray Leitling® covers upper airway inflammation such as allergic rhinitis, and treats asthma, innovative inhalation formulations Enzhuorun® BISHELLE® and Enmingrun® BISHELLER® deeply cultivate asthma Long-term control of chronic respiratory diseases, GPN01564 fills the gap in RSV-specific antiviral treatment and promotes the upgrading of the platform from a product cluster for chronic airway diseases to a systemic respiratory treatment system. The field of respiratory and critical care is one of the Group's core strategic areas. The products on sale cover various indications such as rhinitis, bronchitis, pneumonia, asthma, and chronic obstructive pulmonary disease. Among them, the core product Cheno® is an exclusive product in China and has been recommended by many guidelines and expert consensus. On the payment side, Lightling ® was included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” (National Medical Insurance Drug Catalogue) for the first time this year. Enzhuorun® and Enmingrun® BISHLE® successfully renewed the national medical insurance drug catalogue, helping to improve patient drug accessibility and accelerate market penetration.

GPN01564 is a global innovative drug independently developed by the Group based on a self-built anti-infective innovation platform. With the Wuhan Optics Valley International R&D Center as the core, the platform has built a global anti-infective innovation R&D network covering the entire chain of “early detection — process development — clinical transformation”. The R&D center has a construction area of more than 13,000 square meters and is equipped with international advanced scientific research equipment. It can carry out research and development of small-molecule drugs, polypeptide drugs, and high-end complex dosage forms, etc., and has established special laboratories for pharmacodynamics evaluation, process thermal safety evaluation, crystallization technology, and continuous flow process research. The platform has the qualifications of a national enterprise technology center and an R&D and innovation technology platform at the provincial level or above, and has established a national postdoctoral research workstation. With the mission of “overcoming major infectious diseases”, the platform has laid out high-burden racetracks such as RSV, sepsis, acute respiratory distress syndrome (ARDS), influenza, herpes virus, novel coronavirus infections, and gram-negative bacteria in the field of respiratory virus infections to directly address unmet clinical needs; it has built a continuous project hierarchy from candidate molecule discovery, preclinical research, registration and registration to clinical development, and is progressing in an orderly manner. In the future, the Group will continue to strengthen its strategic investment in the platform, focusing on improving the level of source innovation, molecular discovery efficiency and clinical transformation capabilities, accelerating the upgrading of the platform to a systematic treatment system, and comprehensively contributing to the long-term high-quality development of the respiratory and critical care sector in the field of anti-infection.

The Group has always attached great importance to research and development of innovative products and advanced technology, with patient needs as the core, scientific and technological innovation, increasing investment in innovative global products and advanced technology, enriching and improving product pipelines and industrial layout in response to unmet clinical needs, adopting a “global operation layout, dual cycle business development” strategy to form a new pattern of domestic and international dual cycle linkage development and mutual promotion, giving full play to the Group's industrial advantages and R&D strength, and quickly launch innovative scientific and technological products to provide patients around the world with more advanced and diverse treatment plans.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending